Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):286-8. doi: 10.1016/j.clml.2011.03.017. Epub 2011 Apr 20.

Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.

Author information

1
Department of Dermatology, University of Texas Medical School at Houston and MD Anderson Cancer Center, Houston, TX, USA. Stephanie.J.Martin@uth.tmc.edu

Abstract

B-cell lymphoproliferative disorders are a continuum from benign cutaneous lymphoid hyperplasia (CLH) or "pseudolymphoma" to primary cutaneous B-cell lymphoma (PCBCL). Historically, CLH was treated with a combination of antibiotics, topical or intralesional corticosteroids, and/or localized radiotherapy. Rituximab, a monoclonal antibody that targets the CD20 marker on B cells, is an effective and well-reported treatment for PCBCL. We review the pathogenesis and current treatments of B-cell lymphoproliferative disorders and assess the role of rituximab for potential therapy in the setting of refractory CLH. We describe a case of CLH that was treated with intralesional rituximab. The patient had notable clinical improvement over the treatment period with rituximab. Because of some persistent and recurrent erythematous areas, topical tacrolimus was initiated, with significant clinical improvement. There were no reported side effects. Management of CLH with intralesional rituximab has been described. The treatment presented in this report substantiates rituximab as a reasonable therapeutic option for refractory CLH after failure of several other widely accepted treatments. Treatment with intralesional rituximab should be reserved for patients with documented CD20(+) lesions.

PMID:
21658657
DOI:
10.1016/j.clml.2011.03.017
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center